𝕏
Latest
Business

Alnylam seeks new commercial chief as Amvuttra sales falter

Alnylam Pharmaceuticals (ALNY) is searching for a new chief commercial officer after Tolga Tanguler, who held the role for six years, left the company.

No reason was given for his departure, and Tanguler did not provide a comment. The exit appears to take effect immediately. Alnylam said it was working with an executive search firm to select its next chief commercialization officer and expected to provide an update “in due course”.

The change comes as Alnylam’s commercial performance has fallen short of expectations this year. Its shares fell 20 per cent after third-quarter results as sales of Amvuttra, its most important drug, again disappointed analysts and investors.

Amvuttra, an RNA interference therapy, was first approved in 2022 for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Its label was expanded in 2025 to cover certain patients with wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy.

Sales have lost momentum, prompting the company to cut its guidance. In July, shares dropped as much as 29 per cent after second-quarter results showed weak Amvuttra sales, a lowered full-year forecast and renewed concern over the transthyretin amyloidosis franchise. On the investor call, Tanguler sought to reassure analysts that the launch was progressing well and that the drug’s long-term potential was intact.

Amvuttra generated $1.13bn in the third quarter, but that was not enough to reassure investors. Myles Minter, an analyst at William Blair, said the “back-to-back quarters of headwinds undoubtedly call into question the growth outlook for the franchise”, making it difficult to assess near-term 2027 revenue estimates as well as the longer-term trajectory.

Greenstreet said Alnylam had “significant opportunities to reach more patients with our medicines, advance our pipeline and continue building a sustainable, high-performing business”.

Alongside the announcement, Alnylam unveiled a $1bn share repurchase program. Amy Schulman, chair of the board, said the authorization reflected the company’s “confidence in that future and our commitment to disciplined capital allocation”.

APCompany profileAlnylam PharmaceuticalsKey facts and frequently asked questions

Related coverage

All news →